Notch and disease: A growing field

Seminars in Cell and Developmental Biology

Volumn 23, Issue 4, 2012, Pages 473-480

  Louvi, Angeliki ^a   Artavanis Tsakonas, Spyros ^b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c l'alimentation et l'Environnement   (France)

Author keywords

CADASIL; Dominant syndrome; Notch; Pleiotropy

Indexed keywords

NOTCH RECEPTOR;

ADULT STEM CELL; BRAIN ISCHEMIA; CADASIL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; GENE TARGETING; HUMAN; METABOLIC BONE DISEASE; MULTIINFARCT DEMENTIA; NONHUMAN; ONCOGENE; PATHOLOGY; PLEIOTROPY; REVIEW; SIGNAL TRANSDUCTION; SKELETON; TRANSGENIC MOUSE;

EID: 84861987033     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2012.02.005     Document Type: Review

References (119)

1. Wharton K.A., Johansen K.M., Xu T., Artavanis-Tsakonas S. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell 1985, 43(3 Pt 2):567-581.
2. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: cell fate control and signal integration in development. Science 1999, 284(5415):770-776.
3. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137(2):216-233.
4. Bray S.J. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006, 7(9):678-689.
5. Levitan D., Greenwald I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 1995, 377(6547):351-354.
6. Kankel M.W., Hurlbut G.D., Upadhyay G., Yajnik V., Yedvobnick B., Artavanis-Tsakonas S. Investigating the genetic circuitry of mastermind in Drosophila: a notch signal effector. Genetics 2007, 177(4):2493-2505.
7. Peter I.S., Davidson E.H. A gene regulatory network controlling the embryonic specification of endoderm. Nature 2011, 474(7353):635-639.
8. Hurlbut G.D., Kankel M.W., Lake R.J., Artavanis-Tsakonas S. Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol 2007, 19(2):166-175.
9. Saj A., Arziman Z., Stempfle D., van Belle W., Sauder U., Horn T., et al. A combined ex vivo and in vivo RNAi screen for notch regulators in Drosophila reveals an extensive notch interaction network. Dev Cell 2010, 18(5):862-876.
10. Dorer D.R., Ezekiel D.H., Christensen A.C. The Triplo-lethal locus of Drosophila: reexamination of mutants and discovery of a second-site suppressor. Genetics 1995, 141(3):1037-1042.
11. Artavanis-Tsakonas S., Muskavitch M.A. Notch: the past, the present, and the future. Curr Top Dev Biol 2010, 92:1-29.
12. Mazzone M., Selfors L.M., Albeck J., Overholtzer M., Sale S., Carroll D.L., et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci USA 2010, 107(11):5012-5017.
13. Fortini M.E., Bilder D. Endocytic regulation of Notch signaling. Curr Opin Genet Dev 2009, 19(4):323-328.
14. Yamamoto S., Charng W.L., Bellen H.J. Endocytosis and intracellular trafficking of Notch and its ligands. Curr Top Dev Biol 2010, 92:165-200.
15. Wilkin M., Tongngok P., Gensch N., Clemence S., Motoki M., Yamada K., et al. Drosophila HOPS and AP-3 complex genes are required for a Deltex-regulated activation of notch in the endosomal trafficking pathway. Dev Cell 2008, 15(5):762-772.
16. Hori K., Sen A., Kirchhausen T., Artavanis-Tsakonas S. Synergy between the ESCRT-III complex and Deltex defines a ligand-independent Notch signal. J Cell Biol 2011, 195(6):1005-1015.
17. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010, 16(12):3141-3152.
18. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., de Leon G.P., Chen Y., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464(7291):1052-1057.
19. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., et al. TAN-1: the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66(4):649-661.
20. Koch U., Radtke F. Notch in T-ALL: new players in a complex disease. Trends Immunol 2011, 32(9):434-442.
21. Weng A.P., Ferrando A.A., Lee W., Morris J.P.t., Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306(5694):269-271.
22. Lee S.Y., Kumano K., Nakazaki K., Sanada M., Matsumoto A., Yamamoto G., et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009, 100(5):920-926.
23. Koch U., Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci 2007, 64(21):2746-2762.
24. van Es J.H., van Gijn M.E., Riccio O., van den Born M., Vooijs M., Begthel H., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435(7044):959-963.
25. Demehri S., Turkoz A., Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009, 16(1):55-66.
26. Koch U., Radtke F. Notch signaling in solid tumors. Curr Top Dev Biol 2010, 92:411-455.
27. Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003, 33(3):416-421.
28. Ranganathan P., Weaver K.L., Capobianco A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011, 11(5):338-351.
29. Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M., et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 2011, 108(43):17761-17766.
30. Fre S., Pallavi S.K., Huyghe M., Lae M., Janssen K.P., Robine S., et al. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci USA 2009, 106(15):6309-6314.
31. Kiaris H., Politi K., Grimm L.M., Szabolcs M., Fisher P., Efstratiadis A., et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol 2004, 165(2):695-705.
32. Oda T., Elkahloun A.G., Pike B.L., Okajima K., Krantz I.D., Genin A., et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997, 16(3):235-242.
33. Li L., Krantz I.D., Deng Y., Genin A., Banta A.B., Collins C.C., et al. Alagille syndrome is caused by mutations in human Jagged1: which encodes a ligand for Notch1. Nat Genet 1997, 16(3):243-251.
34. Alagille D., Odievre M., Gautier M., Dommergues J.P. Hepatic ductular hypoplasia associated with characteristic facies: vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr 1975, 86(1):63-71.
35. Turnpenny P.D., Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2012, 20(3):251-257.
36. McDaniell R., Warthen D.M., Sanchez-Lara P.A., Pai A., Krantz I.D., Piccoli D.A., et al. NOTCH2 mutations cause Alagille syndrome: a heterogeneous disorder of the Notch signaling pathway. Am J Hum Genet 2006, 79(1):169-173.
37. Kamath B.M., Podkameni G., Hutchinson A.L., Leonard L.D., Gerfen J., Krantz I.D., et al. Renal anomalies in Alagille syndrome: a disease-defining feature. Am J Med Genet A 2011, Nov 21. doi:10.1002/ajmg.a.34369. [Epub ahead of print].
38. McCright B., Lozier J., Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 2002, 129(4):1075-1082.
39. Gruneberg H. Genetical studies on the skeleton of the mouse. XXIX. PUDGY. Genet Res 1961, 2(2):384-393.
40. Kusumi K., Sun E.S., Kerrebrock A.W., Bronson R.T., Chi D.C., Bulotsky M.S., et al. The mouse pudgy mutation disrupts Delta homologue Dll3 and initiation of early somite boundaries. Nat Genet 1998, 19(3):274-278.
41. Bulman M.P., Kusumi K., Frayling T.M., McKeown C., Garrett C., Lander E.S., et al. Mutations in the human delta homologue: DLL3, cause axial skeletal defects in spondylocostal dysostosis. Nat Genet 2000, 24(4):438-441.
42. Turnpenny P.D., Whittock N., Duncan J., Dunwoodie S., Kusumi K., Ellard S. Novel mutations in DLL3: a somitogenesis gene encoding a ligand for the Notch signalling pathway, cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis. J Med Genet 2003, 40(5):333-339.
43. Chapman G., Sparrow D.B., Kremmer E., Dunwoodie S.L. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet 2011, 20(5):905-916.
44. Sparrow D.B., Chapman G., Wouters M.A., Whittock N.V., Ellard S., Fatkin D., et al. Mutation of the LUNATIC FRINGE gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. Am J Hum Genet 2006, 78(1):28-37.
45. Sparrow D.B., Guillen-Navarro E., Fatkin D., Dunwoodie S.L. Mutation of Hairy-and-Enhancer-of-Split-7 in humans causes spondylocostal dysostosis. Hum Mol Genet 2008, 17(23):3761-3766.
46. Sparrow D.B., Sillence D., Wouters M.A., Turnpenny P.D., Dunwoodie S.L. Two novel missense mutations in HAIRY-AND-ENHANCER-OF-SPLIT-7 in a family with spondylocostal dysostosis. Eur J Hum Genet 2010, 18(6):674-679.
47. Whittock N.V., Sparrow D.B., Wouters M.A., Sillence D., Ellard S., Dunwoodie S.L., et al. Mutated MESP2 causes spondylocostal dysostosis in humans. Am J Hum Genet 2004, 74(6):1249-1254.
48. Cornier A.S., Staehling-Hampton K., Delventhal K.M., Saga Y., Caubet J.F., Sasaki N., et al. Mutations in the MESP2 gene cause spondylothoracic dysostosis/Jarcho-Levin syndrome. Am J Hum Genet 2008, 82(6):1334-1341.
49. Gucev Z.S., Tasic V., Pop-Jordanova N., Sparrow D.B., Dunwoodie S.L., Ellard S., et al. Autosomal dominant spondylocostal dysostosis in three generations of a Macedonian family: negative mutation analysis of DLL3, MESP2, HES7, and LFNG. Am J Med Genet A 2010, 152A(6):1378-1382.
50. Sparrow D.B., Chapman G., Dunwoodie S.L. The mouse notches up another success: understanding the causes of human vertebral malformation. Mamm Genome 2011, 22(7-8):362-376.
51. Hajdu N., Kauntze R. Cranioskeletal dysplasia. Br J Radiol 1948, 21:42-48.
52. Cheney W.D. Acro-osteolysis. Am J Roentgenol Radium Ther Nucl Med 1965, 94:595-607.
53. Simpson M.A., Irving M.D., Asilmaz E., Gray M.J., Dafou D., Elmslie F.V., et al. Mutations in NOTCH2 cause Hajdu-Cheney syndrome: a disorder of severe and progressive bone loss. Nat Genet 2011, 43(4):303-305.
54. Isidor B., Lindenbaum P., Pichon O., Bezieau S., Dina C., Jacquemont S., et al. Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat Genet 2011, 43(4):306-308.
55. Majewski J., Schwartzentruber J.A., Caqueret A., Patry L., Marcadier J., Fryns J.P., et al. Mutations in NOTCH2 in families with Hajdu-Cheney syndrome. Hum Mutat 2011, 32(10):1114-1117.
56. Isidor B., Le Merrer M., Exner G.U., Pichon O., Thierry G., Guiochon-Mantel A., et al. Serpentine fibula-polycystic kidney syndrome caused by truncating mutations in NOTCH2. Hum Mutat 2011, 32(11):1239-1242.
57. Gray M.J., Kim C.A., Bertola D.R., Arantes P.R., Stewart H., Simpson M.A., et al. Serpentine fibula polycystic kidney syndrome is part of the phenotypic spectrum of Hajdu-Cheney syndrome. Eur J Hum Genet 2012, 20(1):122-124.
58. Kung A.W., Xiao S.M., Cherny S., Li G.H., Gao Y., Tso G., et al. Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies. Am J Hum Genet 2010, 86(2):229-239.
59. Hilton M.J., Tu X., Wu X., Bai S., Zhao H., Kobayashi T., et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008, 14(3):306-314.
60. Engin F., Yao Z., Yang T., Zhou G., Bertin T., Jiang M.M., et al. Dimorphic effects of Notch signaling in bone homeostasis. Nat Med 2008, 14(3):299-305.
61. High F.A., Epstein J.A. The multifaceted role of Notch in cardiac development and disease. Nat Rev Genet 2008, 9(1):49-61.
62. MacGrogan D., Nus M., de la Pompa J.L. Notch signaling in cardiac development and disease. Curr Top Dev Biol 2010, 92:333-365.
63. Garg V., Muth A.N., Ransom J.F., Schluterman M.K., Barnes R., King I.N., et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437(7056):270-274.
64. Mohamed S.A., Aherrahrou Z., Liptau H., Erasmi A.W., Hagemann C., Wrobel S., et al. Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem Biophys Res Commun 2006, 345(4):1460-1465.
65. McElhinney D.B., Krantz I.D., Bason L., Piccoli D.A., Emerick K.M., Spinner N.B., et al. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation 2002, 106(20):2567-2574.
66. Krantz I.D., Smith R., Colliton R.P., Tinkel H., Zackai E.H., Piccoli D.A., et al. Jagged1 mutations in patients ascertained with isolated congenital heart defects. Am J Med Genet 1999, 84(1):56-60.
67. Eldadah Z.A., Hamosh A., Biery N.J., Montgomery R.A., Duke M., Elkins R., et al. Familial tetralogy of Fallot caused by mutation in the jagged1 gene. Hum Mol Genet 2001, 10(2):163-169.
68. Bauer R.C., Laney A.O., Smith R., Gerfen J., Morrissette J.J., Woyciechowski S., et al. Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis. Hum Mutat 2010, 31(5):594-601.
69. Joutel A., Corpechot C., Ducros A., Vahedi K., Chabriat H., Mouton P., et al. Notch3 mutations in CADASIL: a hereditary adult-onset condition causing stroke and dementia. Nature 1996, 383(6602):707-710.
70. Joutel A., Dodick D.D., Parisi J.E., Cecillon M., Tournier-Lasserve E., Bousser M.G. De novo mutation in the Notch3 gene causing CADASIL. Ann Neurol 2000, 47(3):388-391.
71. Coto E., Menendez M., Navarro R., Garcia-Castro M., Alvarez V. A new de novo Notch3 mutation causing CADASIL. Eur J Neurol 2006, 13(6):628-631.
72. Tuominen S., Juvonen V., Amberla K., Jolma T., Rinne J.O., Tuisku S., et al. Phenotype of a homozygous CADASIL patient in comparison to 9 age-matched heterozygous patients with the same R133C Notch3 mutation. Stroke 2001, 32(8):1767-1774.
73. Liem M.K., Lesnik Oberstein S.A., Vollebregt M.J., Middelkoop H.A., van der Grond J., Helderman-van den Enden A.T. Homozygosity for a NOTCH3 mutation in a 65-year-old CADASIL patient with mild symptoms: a family report. J Neurol 2008, 255(12):1978-1980.
74. Chabriat H., Joutel A., Dichgans M., Tournier-Lasserve E., Bousser M.G. Cadasil. Lancet Neurol 2009, 8(7):643-653.
75. Fouillade C., Monet-Lepretre M., Baron-Menguy C., Joutel A. Notch signaling in smooth muscle cells during development and disease. Cardiovasc Res 2012, Feb 20. [Epub ahead of print].
76. Dziewulska D., Lewandowska E. Pericytes as a new target for pathological processes in CADASIL. Neuropathology 2012, Jan 12. doi:10.1111/j.1440-1789.2011.01290.x. [Epub ahead of print].
77. Baudrimont M., Dubas F., Joutel A., Tournier-Lasserve E., Bousser M.G. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke 1993, 24(1):122-125.
78. Ruchoux M.M., Guerouaou D., Vandenhaute B., Pruvo J.P., Vermersch P., Leys D. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol (Berl) 1995, 89(6):500-512.
79. Lewandowska E., Dziewulska D., Parys M., Pasennik E. Ultrastructure of granular osmiophilic material deposits (GOM) in arterioles of CADASIL patients. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre. Pol Acad Sci 2011, 49(3):174-180.
80. Tikka S., Mykkanen K., Ruchoux M.M., Bergholm R., Junna M., Poyhonen M., et al. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain 2009, 132(Pt 4):933-939.
81. Arboleda-Velasquez J.F., Manent J., Lee J.H., Tikka S., Ospina C., Vanderburg C.R., et al. Hypomorphic Notch 3 alleles link Notch signaling to ischemic cerebral small-vessel disease. Proc Natl Acad Sci USA 2011, 108(21):E128-E135.
82. Joutel A., Vahedi K., Corpechot C., Troesch A., Chabriat H., Vayssiere C., et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 1997, 350(9090):1511-1515.
83. Dichgans M., Ludwig H., Muller-Hocker J., Messerschmidt A., Gasser T. Small in-frame deletions and missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGF-like repeat domains. Eur J Hum Genet 2000, 8(4):280-285.
84. Viitanen M., Kalimo H. CADASIL: hereditary arteriopathy leading to multiple brain infarcts and dementia. Ann NY Acad Sci 2000, 903:273-284.
85. Donahue C.P., Kosik K.S. Distribution pattern of Notch3 mutations suggests a gain-of-function mechanism for CADASIL. Genomics 2004, 83(1):59-65.
86. Spinner N.B. CADASIL: Notch signaling defect or protein accumulation problem?. J Clin Invest 2000, 105(5):561-562.
87. Karlstrom H., Beatus P., Dannaeus K., Chapman G., Lendahl U., Lundkvist J. A CADASIL-mutated Notch 3 receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling. Proc Natl Acad Sci USA 2002, 99(26):17119-17124.
88. Haritunians T., Boulter J., Hicks C., Buhrman J., DiSibio G., Shawber C., et al. CADASIL Notch3 mutant proteins localize to the cell surface and bind ligand. Circ Res 2002, 90(5):506-508.
89. Joutel A., Monet M., Domenga V., Riant F., Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling pathway. Am J Hum Genet 2004, 74(2):338-347.
90. Peters N., Herzog J., Opherk C., Dichgans M. A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke 2004, 35(7):1603-1608.
91. Arboleda-Velasquez J.F., Rampal R., Fung E., Darland D.C., Liu M., Martinez M.C., et al. CADASIL mutations impair Notch3 glycosylation by Fringe. Hum Mol Genet 2005, 14(12):1631-1639.
92. Opherk C., Duering M., Peters N., Karpinska A., Rosner S., Schneider E., et al. CADASIL mutations enhance spontaneous multimerization of NOTCH3. Hum Mol Genet 2009, 18(15):2761-2767.
93. Duering M., Karpinska A., Rosner S., Hopfner F., Zechmeister M., Peters N., et al. Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. Hum Mol Genet 2011, 20(16):3256-3265.
94. Takahashi K., Adachi K., Yoshizaki K., Kunimoto S., Kalaria R.N., Watanabe A. Mutations in NOTCH3 cause the formation and retention of aggregates in the endoplasmic reticulum: leading to impaired cell proliferation. Hum Mol Genet 2010, 19(1):79-89.
95. Krebs L.T., Xue Y., Norton C.R., Sundberg J.P., Beatus P., Lendahl U., et al. Characterization of Notch3-deficient mice: normal embryonic development and absence of genetic interactions with a Notch1 mutation. Genesis 2003, 37(3):139-143.
96. Domenga V., Fardoux P., Lacombe P., Monet M., Maciazek J., Krebs L.T., et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004, 18(22):2730-2735.
97. Kitamoto T., Takahashi K., Takimoto H., Tomizuka K., Hayasaka M., Tabira T., et al. Functional redundancy of the Notch gene family during mouse embryogenesis: analysis of Notch gene expression in Notch3-deficient mice. Biochem Biophys Res Commun 2005, 331(4):1154-1162.
98. Mitchell K.J., Pinson K.I., Kelly O.G., Brennan J., Zupicich J., Scherz P., et al. Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet 2001, 28(3):241-249.
99. Arboleda-Velasquez J.F., Zhou Z., Shin H.K., Louvi A., Kim H.H., Savitz S.I., et al. Linking Notch signaling to ischemic stroke. Proc Natl Acad Sci USA 2008, 105(12):4856-4861.
100. Jin S., Hansson E.M., Tikka S., Lanner F., Sahlgren C., Farnebo F., et al. Notch signaling regulates platelet-derived growth factor receptor-beta expression in vascular smooth muscle cells. Circ Res 2008, 102(12):1483-1491.
101. Joutel A. Pathogenesis of CADASIL: transgenic and knock-out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature. Bioessays 2011, 33(1):73-80.
102. Lundkvist J., Zhu S., Hansson E.M., Schweinhardt P., Miao Q., Beatus P., et al. Mice carrying a R142C Notch 3 knock-in mutation do not develop a CADASIL-like phenotype. Genesis 2005, 41(1):13-22.
103. Wallays G., Nuyens D., Silasi-Mansat R., Souffreau J., Callaerts-Vegh Z., Van Nuffelen A., et al. Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Arterioscler Thromb Vasc Biol 2011, 31(12):2881-2888.
104. Ruchoux M.M., Domenga V., Brulin P., Maciazek J., Limol S., Tournier-Lasserve E., et al. Transgenic mice expressing mutant Notch3 develop vascular alterations characteristic of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Am J Pathol 2003, 162(1):329-342.
105. Monet M., Domenga V., Lemaire B., Souilhol C., Langa F., Babinet C., et al. The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3 function in vivo. Hum Mol Genet 2007, 16(8):982-992.
106. Monet-Lepretre M., Bardot B., Lemaire B., Domenga V., Godin O., Dichgans M., et al. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Brain 2009, 132(Pt 6):1601-1612.
107. Joutel A., Monet-Lepretre M., Gosele C., Baron-Menguy C., Hammes A., Schmidt S., et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest 2010, 120(2):433-445.
108. Arboleda-Velasquez J.F., Lopera F., Lopez E., Frosch M.P., Sepulveda-Falla D., Gutierrez J.E., et al. C455R notch3 mutation in a Colombian CADASIL kindred with early onset of stroke. Neurology 2002, 59(2):277-279.
109. Kato H., Taniguchi Y., Kurooka H., Minoguchi S., Sakai T., Nomura-Okazaki S., et al. Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development 1997, 124(20):4133-4141.
110. Minoguchi S., Taniguchi Y., Kato H., Okazaki T., Strobl L.J., Zimber-Strobl U., et al. RBP-L: a transcription factor related to RBP-Jkappa. Mol Cell Biol 1997, 17(5):2679-2687.
111. Wang S., Sdrulla A.D., diSibio G., Bush G., Nofziger D., Hicks C., et al. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 1998, 21(1):63-75.
112. Emery B. Regulation of oligodendrocyte differentiation and myelination. Science 2010, 330(6005):779-782.
113. John G.R., Shankar S.L., Shafit-Zagardo B., Massimi A., Lee S.C., Raine C.S., et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002, 8(10):1115-1121.
114. Nakahara J., Kanekura K., Nawa M., Aiso S., Suzuki N. Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest 2009, 119(1):169-181.
115. Brosnan C.F., John G.R. Revisiting Notch in remyelination of multiple sclerosis lesions. J Clin Invest 2009, 119(1):10-13.
116. Karbowniczek M., Zitserman D., Khabibullin D., Hartman T., Yu J., Morrison T., et al. The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest 2010, 120(1):93-102.
117. Ma D., Bai X., Zou H., Lai Y., Jiang Y. Rheb GTPase controls apoptosis by regulating interaction of FKBP38 with Bcl-2 and Bcl-XL. J Biol Chem 2010, 285(12):8621-8627.
118. Pear W.S. New roles for Notch in tuberous sclerosis. J Clin Invest 2010, 120(1):84-87.
119. de la Pompa J.L., Epstein J.A. Coordinating tissue interactions: notch signaling in cardiac development and disease. Dev Cell 2012, 22(2):244-254.